Welcome to our dedicated page for AMAG news (Ticker: AMAG), a resource for investors and traders seeking the latest updates and insights on AMAG stock.
AMAG Pharmaceuticals, Inc. (AMAG) is a biopharmaceutical innovator focused on therapeutic iron treatments and women's health solutions. This page provides centralized access to official announcements, financial updates, and strategic developments impacting the company's trajectory in healthcare innovation.
Investors and industry professionals will find timely updates on AMAG's product portfolio, including Feraheme for iron deficiency anemia and collaborations advancing medical safety technologies. The resource aggregates earnings reports, regulatory milestones, and partnership announcements to support data-driven decision-making.
Key content categories include treatment approvals, acquisition developments (such as the Perosphere Pharmaceuticals integration), leadership changes affecting corporate strategy, and research advancements across AMAG's therapeutic areas. All materials maintain compliance with financial disclosure standards.
Bookmark this page for streamlined monitoring of AMAG's progress in addressing critical health needs through biopharmaceutical innovation. Regular updates ensure stakeholders remain informed about developments directly influencing the company's market position and therapeutic impact.
Sensorion (Euronext Paris: ALSEN) has appointed Scott D. Myers as Chairman of its Board of Directors, succeeding Edwin Moses who is stepping down on
AMAG Pharmaceuticals has submitted a response to the FDA's Notice of Opportunity for a Hearing regarding the proposed withdrawal of approval for Makena, the only FDA-approved treatment to reduce preterm birth. This response emphasizes the treatment's clinical effectiveness, especially among minority populations, and the public health implications of its potential withdrawal. AMAG, alongside its new owner Covis Pharma, is committed to conducting further studies to maintain Makena's availability and effectiveness in addressing preterm birth risks, particularly for high-risk groups.
On November 16, 2020, Covis Group completed its acquisition of AMAG Pharmaceuticals for $13.75 per share, transitioning AMAG into an indirect wholly owned subsidiary of Covis. This strategic move aims to enhance Covis' portfolio in women's health and hematology/oncology, enabling the company to expand its therapeutic solutions. CEO Michael Porter highlighted the acquisition as a milestone for Covis, emphasizing the importance of AMAG’s products like Feraheme®, Makena®, and Ciraparantag. The merger positions Covis to support patients more effectively with its expanded offerings.
Covis Group has announced a cash tender offer for AMAG Pharmaceuticals, valuing the company at $13.75 per share, totaling approximately $647 million. This offer represents a 46% premium over AMAG's closing price on September 30, 2020. The tender offer is set to expire on November 12, 2020, and is contingent upon the tendering of at least a majority of AMAG's outstanding shares. If successful, AMAG will become a wholly owned subsidiary of Covis. The filings for the tender offer and AMAG's board recommendation will be submitted to the SEC.
AMAG Pharmaceuticals (NASDAQ: AMAG) has requested a public hearing with the FDA regarding the proposed withdrawal of its approval for Makena, a treatment aimed at reducing preterm birth. Despite the FDA's concerns stemming from the PROLONG trial, which showed no significant difference in outcomes, AMAG emphasizes the treatment's long-standing use and its importance for high-risk patients. The company plans to submit further documentation to support its case. Additionally, Covis Pharma is set to acquire AMAG, pending usual closing conditions.
AMAG Pharmaceuticals received a notice from the FDA proposing to withdraw approval for its product, Makena, which is used to reduce preterm birth in at-risk women. The company has 15 days to respond, with the option to request a hearing. Until then, Makena will remain on the market. AMAG is committed to retaining access to this FDA-approved treatment, citing its importance in preventing preterm births. Despite the FDA's proposal, the company expects its merger with Covis Pharma to close in November 2020.
Covis Group has announced a tender offer to acquire AMAG Pharmaceuticals for $13.75 per share, valuing the deal at approximately $647 million, inclusive of debt. This acquisition represents a premium of 46% over AMAG's last closing price before the announcement. Covis aims to enhance its therapeutic portfolio with AMAG’s leading treatments, anticipating completing the transaction by November 2020, pending customary closing conditions. Both companies' boards have unanimously approved the deal, which includes financing through cash reserves and debt commitments.
AMAG Pharmaceuticals (NASDAQ: AMAG) has announced that CEO Scott Myers and CFO Brian Piekos will engage in a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 10:30 a.m. ET. The event will be available via live audio webcast on AMAG’s investor website, with a replay accessible for 30 days post-event. AMAG focuses on delivering innovative biopharmaceutical products to address unmet medical needs across various therapeutic areas.
AMAG Pharmaceuticals reported a total revenue of $52.8 million for Q2 2020, down from $77.8 million in Q2 2019, significantly impacted by COVID-19 and FDA recommendations. Feraheme and Makena revenues were $29.6 million and $22.3 million, respectively. The company recorded an operating loss of $7.0 million and an adjusted EBITDA loss of $1.7 million. AMAG reissued financial guidance forecasting 2020 revenue between $225 million and $255 million, aiming for positive adjusted EBITDA in the second half. A strategic partnership with Norgine for ciraparantag aims to strengthen its pipeline.
